CureLab Oncology Inc is a biotechnology company based in Boston, MA, dedicated to developing innovative anti-cancer biologics. Their lead product, Elenagen, is a plasmid supercoiled circular DNA encoding gene p62 SQSTM1, which has shown promising results in reversing tumor grade, altering the tumor microenvironment, enhancing the effects of other cancer therapies, reducing chronic inflammation, and stimulating an immune response against tumors. The company has successfully completed international Phase I and IIa clinical trials for Elenagen, demonstrating both safety and clinical benefits, and is now preparing for Phase II trials within the United States.
Generated from the website